A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The study consists of two parts. Part A will evaluate the safety and tolerability of
intravenous LAT8881 in healthy volunteers using an ascending dose schedule. Part B will
evaluate the analgesic efficacy of a single intravenous dose of LAT8881, compared with
placebo, in patients with lumbar radicular pain.
Healthy volunteers are not accepted for Part B.